Metoprolol Succinate Tablet, Film Coated, Extended Release
Product Images NDC 0904-6322

4 FDA label images from Major Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Metoprolol Succinate (NDC 0904-6322). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C4759e35 8d53 E25c 8e52 Ffa976bf7a8d 00

C4759e35 8d53 E25c 8e52 Ffa976bf7a8d 00
The packaging label for Metoprolol succinate extended-release tablets USP displays a 50 mg strength in film-coated, extended-release oral tablet form. The label shows Major Pharmaceuticals as the distributor, includes unit dose packaging of 100 tablets, and features dosage and storage instructions along with a warning about keeping the medication out of reach of children. The NDC code 0904-6323-61 is noted, and the label also references a formulation equivalent to 50 mg metoprolol tartrate.*
FDA Label Image

C4759e35 8d53 E25c 8e52 Ffa976bf7a8d 01

C4759e35 8d53 E25c 8e52 Ffa976bf7a8d 01
The image shows the packaging label for Metoprolol succinate extended-release tablets USP, 25 mg strength. The label indicates unit dose packaging with 100 tablets. It includes the Major Pharmaceuticals name and NDC 0904-6322-61, along with dosage form details as film-coated tablets for oral use. Storage instructions, warnings, manufacturer Dr. Reddy's Laboratories Limited, and distributor information Major Pharmaceuticals, Livonia, MI, are also visible.*
FDA Label Image

Figure

Figure
A forest plot chart showing results for subgroups in the MERIT-HF study. It compares the relative risk and 95% confidence intervals for total mortality, total mortality or all-cause hospitalization, and total mortality or hospitalization for heart failure between metoprolol succinate extended-release tablets and placebo. Subgroups include geographic location, NYHA class, ejection fraction, ischemic etiology, sex, race, myocardial infarction history, diabetes status, hypertension status, and heart rate categories.*
FDA Label Image

Structure

Structure
Chemical structure diagram showing the molecular structure of Metoprolol succinate, highlighting its organic groups and succinate moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.